ABVC BioPharma’s AiBtl BioPharma acquires TT Life Company

ABVC BioPharma announced that the Company’s subsidiary AiBtl BioPharma Inc. acquired TT Life Company. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life. The acquisition of TT Life Company brings together AiBtl’s global development and scaling business expertise with TT Life’s recognized design and manufacturing capabilities in precision medicine. Through this synergy, AiBtl aims to deliver groundbreaking products integrating AI intelligence with everyday life, enhancing consumers’ convenience, efficiency, and wellness worldwide. The acquisition is expected to bring about synergies in research and development, manufacturing, distribution, and financial strength, enabling AiBtl to introduce a diverse range of AI-powered precision medicine tailored to various consumer needs. Leveraging TT Life Company’s product design and manufacturing expertise, AiBtl aims to accelerate the development and commercialization of next-generation precision medicine AI solutions that redefine how people interact with treatment.